Comparative Pharmacology
Head-to-head clinical analysis: CHOLINE C 11 versus PULMOLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLINE C 11 versus PULMOLITE.
CHOLINE C-11 vs PULMOLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choline C-11 is a radioactive diagnostic agent; after intravenous administration, it is taken up by cells and phosphorylated by choline kinase. It accumulates in tissues with high choline metabolism, such as tumors (e.g., prostate cancer), allowing positron emission tomography (PET) imaging. The mechanism for tumor uptake is related to increased cell membrane synthesis and choline kinase activity.
PULMOLITE is a leukotriene receptor antagonist (LTRA) that selectively and competitively inhibits the cysteinyl leukotriene (CysLT1) receptor in the human airway, thereby reducing bronchoconstriction, mucus secretion, and eosinophilic infiltration.
Intravenous: 370-740 MBq (10-20 mCi) as a single injection for PET imaging. Dose depends on patient weight, camera sensitivity, and imaging protocol.
Adults: 200 mg intravenously every 12 hours over 30 minutes.
None Documented
None Documented
The terminal elimination half-life of [11C]choline in plasma is approximately 5-10 minutes. This short half-life is consistent with its use as a PET imaging agent, allowing same-day imaging without significant residual radiation exposure.
Terminal elimination half-life: 12 hours (range 10–14 h) in adults with normal renal function (CrCl >90 mL/min); prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion; approximately 70-80% of administered radioactivity is eliminated in urine within 2 hours, with less than 5% fecal elimination.
Primarily renal (80%) as unchanged drug; 15% fecal via biliary excretion; 5% metabolized.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical